Drug Profile
SDZ 281722
Latest Information Update: 15 Jul 1998
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Skin disorders
Most Recent Events
- 15 Jul 1998 Profile reviewed
- 15 Jul 1998 No-Development-Reported for Cancer in Austria (Unknown route)
- 15 Jul 1998 No-Development-Reported for Cancer in Switzerland (Unknown route)